Blood test triggers early cancer fight in groundbreaking trial
NCT ID NCT04138628
Summary
This study is testing if starting immunotherapy earlier can better control metastatic bladder cancer. It involves 154 adults who have had their bladder removed for cancer. Doctors use a sensitive blood test to detect tiny signs of cancer return and then immediately start the immunotherapy drug atezolizumab, hoping this early action leads to better results than waiting for tumors to grow large enough to see on scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aalborg Universitetshospital
Aalborg, 9100, Denmark
-
Aarhus University Hospital
Aarhus, 8200, Denmark
-
Herlev Hospital
Herlev, 2730, Denmark
-
Odense Universitetshospital
Odense, 5000, Denmark
-
Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.